Uncategorized

Avacta Group plc announces the opening on 5 April 2023 of the first two clinical investigator sites for the phase 1 clinical trial of AVA6000 under its US Investigational New Drug Application.The two sites, Memorial Sloan Kettering Cancer Center in New York and Fred Hutch Cancer Center in Seattle, are now open for patient enrolment […]

DexCom, Inc. announced that it plans to release its first quarter 2023 financial results after market close on Thursday, April 27, 2023.

GC Cell, a Korean biotech company, announced on Apr. 6th that it has successfully attained the international certification for the anti-bribery management system, ISO 37001, from Korea Compliance Initiative, an international certification body.

Immuron Limited is pleased to announce the Q3 FY23 sales* results of its over-the-counter gastrointestinal and digestive health immune supplement Travelan® and Protectyn®.

  In today’s global economy, businesses are increasingly expanding beyond their home countries and hiring employees across borders. This presents a challenge when it comes to managing payroll, as each country has its own unique payroll regulations and tax requirements. That’s wher …

BioInvent International AB, a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, announced that the Annual Report for 2022 has been published.

Sensorion a pioneering clinical-stage biotechnology company which specializes in gene therapies in the inner ear, will present new data supporting GJB2-GT program candidate selection to address hearing loss related to mutations in the GJB2 gene during the Company’s R&D Day taking place , Thursday, April 6, 2023.

Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited, committed to cutting-edge technology innovation and provider of integrated solutions from “Idea to IND”, announced it has entered into a collaboration agreement with ExeVir Bio.

Curis, Inc. announced that on March 31, 2023, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 135,450 shares of Curis common stock to a new employee, with a grant date of March 31, 2023.

Innate Pharma SA announced the filing of its 2022 Universal Registration Document for the year ending December 31, 2022 with the French market authority “Autorité des Marchés Financiers” on April 6, 2023.